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ABSTRACT
Acinetobacter baumannii can cause life-threaten-
ing nosocomial infections associated with high
rates of morbidity and mortality. In recent
years, the increasing number of infections due
to extensively drug-resistant Acinetobacter with
limited treatment options has resulted in a need
for additional therapeutic agents, and a renais-
sance of older, neglected antimicrobials. This
has led to an increased interest in the use of
minocycline to treat these infections. Minocy-
cline has been shown to overcome many resis-
tance mechanisms affecting other tetracyclines
in A. baumannii, including tigecycline. Addi-
tionally, it has favorable pharmacokinetic and
pharmacodynamic properties, as well as excel-
lent in vitro activity against drug-resistant A.
baumannii. Available data support therapeutic
success with minocycline, while ease of dosing
with no need for renal or hepatic dose adjust-
ments and improved safety have made it an
appealing therapy. This review will focus on the
mechanisms of action and resistance to tetra-
cyclines in A. baumannii, the in vitro activity,
pharmacokinetic and pharmacodynamic prop-
erties of minocycline against A. baumannii, and
finally the clinical experience with minocycline
for the treatment of invasive infections due to
this pathogen.
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Acinetobacter baumannii and other Acinetobacter
species can cause multidrug-resistant (MDR)
nosocomial infections, with high morbidity and
mortality rates. MDR A. baumannii, defined as A.
baumannii resistant to more than 3 classes of
antimicrobial agents, has been responsible for a
variety of healthcare-associated infections
within the last two decades [1, 2]. Its ability to
resist environmental stress and cleaning
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methods, and to acquire resistance to multiple
classes of antimicrobial agents, have made this
pathogen more common, and has become one
of the most difficult to manage causes of out-
breaks in the setting of intensive care units
(ICUs) [3, 4]. In the Centers for Disease Control
and Prevention (CDC) Antibiotic Resistance
Threats report of 2013, MDR A. baumannii was
declared a ‘‘serious threat’’ to public health in
the United States [5]. Even more concerning has
been the emergence of extensively drug-resis-
tant or XDR strains of A. baumannii that are
resistant to all but one or two classes of
antimicrobials, and truly pan-drug-resistant
strains resistant to all tested antimicrobials.
Traditionally, carbapenems were considered
the drugs of choice when treating these highly
resistant A. baumannii, but in recent years the
widespread use of these agents has diminished
their clinical activity. Carbapenems were con-
sidered appropriate agents to treat infections
caused by MDR A. baumannii strains, but car-
bapenem-resistant A. baumannii (CRAB) has
rapidly increased in frequency. CRAB accounts
for 65% of A. baumannii pneumonia in the
United States and Europe, while more than 60%
of isolates in Asia have been found to be both
pan-drug and carbapenem-resistant [6]. An
analysis of A. baumannii performed in Detroit,
MI reported decreasing susceptibility to thera-
pies such as ampicillin–sulbactam and car-
bapenems in a rapid fashion. In this study,
susceptibility of A. baumannii to ampi-
cillin–sulbactam decreased from 89% to 40%,
while susceptibility to imipenem decreased
from 99% to 42% from 2003 to 2008 [7]. The
high resistance rates of these organisms has led
to a situation with limited therapeutic options,
where in vitro activity is frequently limited to
the polymyxins, aminoglycosides, tigecycline
and minocycline.
In the setting of carbapenem resistance, sul-
bactam (typically administered as ampi-
cillin–sulbactam) is potentially an option for
the treatment of A. baumannii; however, opti-
mal dosing strategies for sulbactam remain
poorly defined and resistance is increasing.
Polymyxins are often considered an important
treatment option for CRAB in the setting of
sulbactam resistance, but unacceptably high
nephrotoxicity rates and an inability to safely
achieve pharmacodynamic targets has raised
concern regarding the use of these agents. In
mouse lung models of A. baumannii pneumo-
nia, colistin was unable to achieve bacteriostasis
even with the maximum tolerated doses against
2 of the 3 strains tested [8]. Furthermore, data
suggest a clinically relevant increase in resis-
tance of A. baumannii to colistin [9–11]. A recent
surveillance study in the United States showed
that 5.3% of all Acinetobacter strains were resis-
tant to colistin [9], while another surveillance
study in Greece reported an increase in colistin
resistance from 1% in 2012 to 21.1% in 2014
among 1116 CRAB isolates [10]. An analysis
from the Eurofins Surveillance Network
demonstrated that resistance to carbapenems
among Acinetobacter more than doubled in
recent years (21.0% in 2003–2005 and 47.9% in
2009–2012) as did resistance to colistin (2.8% in
2006–2008 and 6.9% in 2009–2012). This same
analysis demonstrated that rates of resistance to
minocycline actually decreased over this time
period from 56.5% in 2003–2005 to 30.5% in
2009–2012 [11]. Currently, when CRAB infec-
tions demonstrate resistance to ampicillin–sul-
bactam (up to 74% in the SENTRY program were
not susceptible to ampicillin–sulbactam per
CLSI breakpoints) [12] and to colistin, the
remaining alternatives for treatment are extre-
mely limited.
While certain aminoglycosides can retain
activity in vitro against CRAB, data suggest that
aminoglycoside monotherapy is inadequate for
infections occurring outside the urinary tract,
and concerns remain regarding nephrotoxicity
associated with this class. A meta-analysis
reported that patients receiving aminoglycoside
therapy had higher mortality rates and higher
rates of microbiological failure than patients
receiving beta-lactams or fluoroquinolones [13].
Antimicrobials such as tigecycline, ceftola-
zone–tazobactam and ceftazidime–avibactam
have more recently come to market; but,
unfortunately, these newer agents are not ideal
for CRAB. Ceftolazone–tazobactam and cef-
tazidime–avibactam have minimal utility in the
treatment of CRAB, given the usual mecha-
nisms of resistance to carbapenems are class D
or B carbapenemases. Both of these
Infect Dis Ther
carbapenemases readily hydrolyze these cepha-
losporins and these enzymes are not inhibited
by either tazobactam or avibactam [11]. While
tigecycline shows excellent in vitro activity
against CRAB, enthusiasm surrounding this
agent has been tempered due to pharmacoki-
netic limitations of the drug, the development
of resistance while on therapy, and its inability
to demonstrate non-inferiority in the treatment
of hospital-acquired and ventilator-associated
pneumonia [14–17]. Due to the continued
emergence and dissemination of resistant A.
baumannii and the limited number of thera-
peutic options, other agents such as minocy-
cline have been investigated for their utility in
the treatment of these pathogens.
Minocycline is a second-generation tetracy-
cline that was first introduced in the 1960s.
While the oral formulation remained available,
the intravenous formulation was taken off the
US market in 2005 due to decreased use. It was
re-introduced in 2009 and has become an
important option for the treatment of mul-
tidrug-resistant organisms, in particular CRAB.
Following reintroduction of minocycline to the
market for the treatment of serious infections,
including an FDA-approved indication for
infections caused by Acinetobacter, there has
been renewed interest in its use. Further
investigation of its use for the treatment of
MDR Acinetobacter infections, including those
caused by carbapenem-resistant and XDR
strains, has occurred due to its in vitro activity
against A. baumannii, more favorable pharma-
cokinetics compared to tigecycline, and its
safety profile. This review will focus on the
tetracycline mechanisms of action and resis-
tance, the in vitro activity of minocycline in
the presence and absence of these resistance
mechanisms, the pharmacokinetics and phar-
macodynamics of minocycline, and finally the
clinical experience with minocycline for the
treatment of invasive infections due to A.
baumannii.
Compliance with Ethics Guidelines
This article is based on previously conducted
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Tetracyclines are a broad-spectrum class of
antimicrobials, including tetracycline, doxycy-
cline, minocycline and tigecycline, which enter
Gram-negative organisms through outer mem-
brane protein channels and cause conforma-
tional changes to the RNA by binding with the
30S ribosomal unit. Tetracyclines bind where
the codon of the mRNA is recognized by the
anticodon of the tRNA [18]. This binding blocks
the entry of aminoacyl transfer RNA into the
site A of the ribosome, which prevents elonga-
tion of the peptide chain [12]. It has been
observed that alterations to the hydrophilic
surface of the tetracycline molecule interferes
with the antimicrobial activity of the drug,
while alterations in the hydrophobic surface of
the drug are less likely to interfere [18]. Doxy-
cycline and minocycline are the more lipophilic
counterparts of tetracycline, which allows for
increased tissue penetration, increased antibac-
terial activity, longer half-lives and broader
spectrums of activity against many bacterial
species, including Acinetobacter species
[12, 19–21].
Resistance to tetracyclines is conferred
through a variety of mechanisms, including
efflux pumps, ribosomal protection proteins,
chemical molecule modification and target site
modifications. Among Gram-negative organ-
isms, the main mechanism leading to tetracy-
cline resistance is through efflux pumps. The
differences in gene-encoding efflux proteins
account for the differences in resistance phe-
notypes to the different agents within the
tetracycline class. There are over 20 efflux pump
encoding genes that have been detected in
Gram-negative organisms, with the most com-
mon being TetA. These efflux pumps lead to a
decrease in tetracycline intracellular concen-
tration by exchanging a proton for the tetracy-
cline cation complex [12, 18]. In vitro efflux
pumps seen in A. baumannii are effective in
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transporting out tetracycline and doxycycline,
but with the exception of the TetB pump, not
minocycline. Recent work by Lomoskaya and
colleagues confirmed that the absence of TetB in
A. baumannii has a negative predictive value of
100% for minocycline resistance (93/93 TetB
negative strains were minocycline susceptible),
whereas the presence of TetB has a 93% positive
predictive value for minocycline resistance,
with only 11/165 (6.7%) isolates being suscep-
tible to minocycline when TetB was present
[22]. Thus, the gene encoding for TetB repre-
sents a potential target for rapid diagnostic gene
testing to quickly determine minocycline
susceptibility.
Tigecycline was synthetically designed to
overcome these efflux pumps and has activity if
either TetA or TetB is present. Unfortunately,
although tigecycline was developed to overcome
many of the efflux pump resistance mechanisms
commonly seen with tetracyclines, rapid devel-
opment of different resistancemechanisms have
been observed. Current literature suggests that
the development of such resistance has been
associated with the TetX gene and, perhaps most
importantly forA. baumannii, the overexpression
of various efflux pumps (AdeABC, AdeIJK,
AdeFGH, AbeM, AdeDE) [23, 24].
Resistance-nodulation-division (RND)-type
efflux pumps, such as AdeABC, have been clo-
sely associated with the development of tige-
cycline resistance. These pumps have been
shown to be more efficient than other types of
efflux pumps in that they export drugs into the
extracellular, rather than periplasmic, space.
Up-regulation of these AdeABC pumps have
been associated with higher MICs and increased
resistance to tigecycline in vitro. Data from
Hornsey and colleagues reported overexpres-
sion of the AdeABC efflux pump in two cases of
tigecycline resistance, which emerged after
tigecycline therapy, as well as a laboratory
mutant with an elevated MIC. In this study,
susceptibility was restored in a resistant isolate
by interrupting the AdeB, which further sup-
ports a role of AdeABC in tigecycline resistance
[25].
Interestingly, the RND pumps previously
mentioned do not appear to impact minocy-
cline susceptibility, and therefore
tigecycline-resistant A. baumannii can remain
susceptible to minocycline. Importantly, these
RND pumps can be selected with clinically rel-
evant concentrations of tigecycline (but not
minocycline) and serve as a mechanism for the
well-described development of tigecycline
resistance while on therapy [26].
In Vitro Activity
It has been shown that minocycline has
increased activity against MDR Acinetobacter
compared to other early generation tetracycli-
nes because of its ability to overcome many of
the tetracycline resistance mechanisms (most
notably TetA). A. baumannii containing oxacili-
nases or metalo-beta-lactamase genes has been
reported to retain a susceptibility profile to
minocycline similar to organisms without these
genes [27]. In one in vitro study, using CLSI
breakpoints, minocycline displayed a 30%
improved susceptibility compared to doxycy-
cline and nearly 60% improved susceptibility
compared to tetracycline against A. baumannii
[12]. Thus, minocycline susceptibility should be
determined by testing directly and not be
determined by a surrogate class approach (i.e.
tigecycline and doxycycline resistance does not
necessarily equal minocycline resistance).
In vitro, minocycline has frequently been
shown to be one of the only available treatment
options for difficult to treat multi drug-resistant
Acinetobacter infections, and as described above is
often the second most active agent behind col-
istin. The antimicrobial activity of minocycline
against A. baumannii was recently evaluated in
two large surveillance studies fromdifferentparts
of the world: the SENTRY antimicrobial surveil-
lance program (2007–2011) [12] and the Tigecy-
cline Evaluation and Surveillance Trial (T.E.S.T,
2005–2011) [28]. In the SENTRY program, 79.1%
of A. baumannii were susceptible to minocycline
(second only to colistin, which had a 98.8%
susceptibility rate), while in the T.E.S.T., A. bau-
manniihad a susceptibility rate of 84.1%, ranging
between 68.5% in East South Central US and
97.4% in New England. Similarly, multidrug-re-
sistant A. baumannii (defined as resistance to 3 or
more classes of antibiotics among beta-lactams,
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aminoglycosides, carbapenems or fluoro-
quinolones) were susceptible to minocycline in
72.1% of cases, (ranging between 54% in the East
South Central US, and 92.3% in New England).
Furthermore, a study by Castanheira and
colleagues assessed A. baumannii isolates col-
lected between 2007 and 2011 and showed that
the only two antimicrobials with greater than
50% susceptibility rates were minocycline and
colistin. Reports of minocycline retaining its
activity in patient isolates that have developed
colistin resistance during colistin therapy also
exist [29]. Importantly, minocycline suscepti-
bility remains high and is not impacted by
carbapenem resistance. Colton and colleagues
reported that isolates retained MIC50 values of
B4.0 lg/mL for minocycline against Acinetobac-
ter species, including carbapenem-resistant iso-
lates [30]. A study performed in Thailand in
CRAB confirmed these results with findings of
MIC50 values of 4 mg/L and MIC90 values of
8 mg/L for minocycline, with 81.4% of isolates
being susceptible [31].
Additionally, it is important to note that
minocycline has also displayed high levels of
synergistic activity with polymyxins in
minocycline-resistant isolates, where 0.5 mg/L
of polymyxin B restored in vitro susceptibility
to minocycline in 167 tested isolates, 88% of
which were resistant to minocycline
monotherapy [32]. This is an important and
encouraging finding given the propensity to use




In comparison to other more recently evaluated
antimicrobials, there exist minimal data relat-
ing to the pharmacokinetics of minocycline.
Studies which have assessed the pharmacoki-
netics of minocycline have found that serum
concentrations are similar to other tetracy-
clines. Receipt of a 200-mg one-time intra-
venous dose has demonstrated peak serum
concentrations ranging from 3 to 8.75 lg/mL
and trough concentrations from 0.6 to 1.9 lg/
mL [21, 33, 34]. After multiple oral doses of
100 mg every 12 h, serum concentrations have
ranged from approximately 0.7 to 3.9 lg/mL
[21, 34, 35]. Similarly, data reported in the
package insert for intravenous minocycline
state peak and trough concentrations of
2.52–6.63 and 0.82–2.64 lg/mL, respectively
[36]. The protein binding of minocycline is
similar to that of tetracycline, with approxi-
mately 76% of the drug being protein-bound
[30, 33]. The half-life of minocycline following
a single dose of either 200 mg or 100 mg is
approximately 12–24 h, which remains clini-
cally unchanged in patients with renal dys-
function [21, 33, 34, 37]. Minocycline is
primarily metabolized by the liver and excreted
through the hepatobiliary system, with only a
small amount of drug eliminated through the
renal route (5–12%) unchanged in the urine
[33, 37]. For these reasons, it has been hypoth-
esized that minocycline elimination is inde-
pendent of renal function and hepatic function.
In a study looking at single intravenous
doses and repeated oral doses of minocycline, it
was reported that there was no evidence of
reduced drug clearance in patients with reduced
renal function, but a possible increase in tissue
distribution [33]. This particular study evalu-
ated 13 male patients with varying degrees of
renal dysfunction, although none were on
dialysis. The authors found that the decline in
individual serum levels of minocycline activity
after intravenous infusion was biphasic and
therefore the pharmacokinetics were consistent
with a two-compartment model. Both the con-
centration of antibiotic in urine and the
cumulative renal excretion were directly related
to kidney function, while the overall clearance
of antibiotic appeared to be independent of
renal function. As minocycline does not seem
to accumulate in renal failure, it is believed that
minocycline can be safely administered to
patients with renal insufficiency without
requiring any dose adjustments [33].
While minocycline has not been shown to
accumulate in renal failure, there exists the
notion that minocycline use in patients with
renal insufficiency may enhance uremia seen in
these patients due to the anti-anabolic processes
associated with the drug on mammalian cells
[33]. Although publications have suggested an
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increase in urea clearance and rises in plasma
urea in patients with renal insufficiency receiv-
ing minocycline, it is unclear in these analyses
whether or not these were related to antian-
abolic actions of the drug or simply a worsening
of the patients’ renal failure [27]. Authors have
suggested that there is a critical level of free
tetracycline that may be associated with
increased urea production and that this level ‘‘is
seldom reached at doses of 200 mg/day of
minocycline’’ [34]. These findings and state-
ments serve as the basis for the package insert
for minocycline carrying a warning to not
exceed a total daily dosage of 200 mg in 24 h in
patients with renal impairment (CrCl\80 mL/
min) [36]. However, assuming that a minocy-
cline dose of 200 mg BID is needed, based on
pharmacokinetic and pharmacodynamic prop-
erties (described below), we would recommend
against dose adjustment downward in these
patients due to concerns of underexposure
(since the half-life and presumably clearance of
the drug would not be expected to change).
Rather, we would suggest that clinicians be
aware of potential antianabolic actions and
closely monitor blood urea nitrogen levels and
for signs/symptoms of uremia, given the serious
nature of infections due to A. baumannii and the
need to meet PK/PD targets.
Minocycline achieves high tissue penetra-
tion and displays excellent oral bioavailability
allowing for expanded clinical uses by giving
providers the ability to easily switch between
the intravenous and oral formulations.
Minocycline is the most lipophilic of all the
tetracyclines because it has a greater partial
coefficient at a neutral pH, and therefore is
believed to be the most potent, with a longer
half-life, better oral absorption and enhanced
tissue penetration compared to other tetracy-
clines. Previous literature has shown that
minocycline has approximately a 20-fold higher
affinity to the ribosome than tetracycline and
in vitro can inhibit translation 2–7 times more
efficiently than tetracycline [18, 38, 39].
The minocycline-free area under the con-
centration time curve to MIC ratio (fAUC/MIC)
is the pharmacokinetic/pharmacodynamic
parameter best associated with effect. Recent
work by Tarazi and colleagues have identified
the free AUC/MIC target to be associated with
bacteriostasis and 1 log bactericidal activity. In
this analysis, the authors explored exposure
response with 6 different A. baumannii isolates
(minocycline MIC’s ranging from 0.03 to
4 mcg/mL) in a rat pneumonia model. In this
model, mean fAUC/MIC values associated with
stasis and 1 log kill were 12.2 (10.6–16.1) and
18.0 (13.1–24.2) mg h/L, respectively [40].
In order to interpret these fAUC/MIC values,
it is essential to evaluate them in the perspec-
tive of achievable free AUCs obtained with
approved dosing strategies. As has been previ-
ously stated in this section, scant pharmacoki-
netic data of minocycline are available, and no
studies overtly evaluate AUC exposures. How-
ever, the analysis by Welling and colleagues
published 40 years ago does report on clearance
rates in patients with normal renal function and
various degrees of renal insufficiency [26].
Interestingly, in this analysis, they found the
clearance rate was the lowest in patients with
normal renal function (1.18 L/h), and slightly
higher in patients with renal insufficiency
(1.84–2.01 L/h). Using the basic pharmacoki-
netic equation Dose = AUC/Clearance, and the
known protein binding of *76%, one can esti-
mate free AUC exposures and ultimately AUC/
MIC ratios with various minocycline dosing
regimens for different organism MICs. For
patients receiving 200–400 mg daily of
minocycline, total area under the concentration
time curve exposures would be expected to
range from 100 to 340 mg h/L, resulting in a
free AUC of 24–82 mg h/L. Thus, even in the
worst case scenario, where the highest clearance
rate (2.01 L/h) and highest MIC in the suscep-
tible range (4 mcg/mL) is utilized, a dose of
200 mg BID (total AUC = 199 mg h/L, free AUC
48 mg h/L) would be expected to achieve bac-
teriostasis (fAUC/MIC = 12), and in most sce-
narios bactericidal activity would be expected.
Importantly, however, these data are limited
in their interpretability given the large variance
in clearance rates reported, the use of 200-mg
daily doses (as opposed to 400-mg daily doses),
and the small study sample sizes. Additionally,
even though minocycline is considered highly
bioavailable with *90% being orally absorbed,
it is unknown if there were confounding factors
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impacting absorption in this study, and it is
possible that higher doses and intravenous
administration could lead to increased expo-
sures further leading to enhanced bactericidal
activity. Although modern pharmacokinetic
data are urgently needed for minocycline
administered in both its oral and intravenous
formulations, data currently available are
encouraging. Importantly, additional PK studies
of IV minocycline in normal subjects, criti-
cally-ill patients and infected patients, and in
patients with chronic renal impairment are
planned (Mike Dudley, personal
communication).
CLINICAL EXPERIENCE
OF MINOCYCLINE FOR MDR
GRAM-NEGATIVE BACILLI
Overview of Clinical Data
Currently, there have been no randomized,
controlled trials that evaluate the efficacy of
minocycline in treatment of MDR Gram-nega-
tive bacterial infections; however, clinical data
provide evidence of its potential role in the
treatment of these difficult to treat pathogens.
Between the years 1998 and 2015, seven retro-
spective studies [16, 41–47] evaluated the use of
oral or intravenous minocycline alone or in
combination with other antimicrobials for the
treatment of MDR A. baumannii. One factor
complicating interpretation of these studies is
the variety of different definitions used by dif-
ferent investigators. MDR A. baumannii was
defined as resistance to 3 or more antimicrobial
classes in one study [42] and resistance to all
frequently tested beta-lactams in another study
[44]. CRAB was defined as carbapenem-resistant
[16, 45] and pan-drug-resistant A. baumannii
was defined as A. baumannii resistant to all
antibiotics excluding polymyxins [46].
The seven studies included 126 patients
between 17 and 85 years old (Table 1), who had
141 identifiable isolates that included the fol-
lowing sources: respiratory tract (91, 74.6%),
blood (22, 18%), bone (11, 9%), skin and soft
tissue (including surgical site infections) (12,
9.8%), urine (2, 1.6%), and others (3, 2.4%). Of
the patients treated, 94 patients received
minocycline combined with another antimi-
crobial agent, 12 patients were treated with
minocycline monotherapy, and 11 patients
received monotherapy with either minocycline
or doxycycline, with the exact agent not speci-
fied [40]. A majority of the patients (72.5%)
received minocycline intravenously. The most
common dose used was 100 mg twice daily,
with or without a loading dose of 200 mg
(overall, 61 subjects received a loading dose).
One study included patients treated with IV
minocycline 200 mg twice daily [16], and in
another study patients treated with oral
minocycline 200 mg every 6 h [46]. Treatment
was administered for a duration that ranged
between 2 days to 7 weeks, according to the
source of infection [44]. Median durations of
therapy from each study is presented in Table 1.
Overall, the clinical success rate of monother-
apy or combination treatment was 78.2%.
Microbiological cure (defined differently across
studies) was reported in 4 studies and ranged
from 50% and 89% (Table 1).
Clinical Data for Monotherapy
Twenty-three patients in five of the studies were
treated with either minocycline or doxycycline
as monotherapy for A. baumannii infection
[42–46]. As previously stated, in one study there
was no differentiation between treatment with
minocycline and doxycycline, and therefore the
data are presented together [40]. The age of the
patients ranged between 15 and 85 years
(Table 1). Of the 22 known sources of A. bau-
mannii isolates, 16 (73%) were from the respi-
ratory tract, 4 (18%) from soft tissues, and 2
(9%) from the bone. There were no bloodstream
infections in this group. The route of minocy-
cline administration was reported in 12 patients
and was intravenous in most cases (92%). The
most commonly used dose was 100 mg twice
daily, although one study treated patients with
200 mg BID. The number of subjects who
received a loading dose could not be deter-
mined. The duration of treatment ranged





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6 weeks in post-fracture infections. In one
study, clinical success was achieved in 81.8% of
subjects [40] and in 100% of subjects in the four
other studies. Microbiological cure was not
available in this group.
Adverse Events Data in All Clinical Studies
Adverse events were reported in five studies
[16, 42, 44, 45, 47]. In one study, a patient
developed eosinophilia and neutropenia [44].
Two studies reported acute kidney injury (oc-
curring in 28% and 18.2% of subjects) which
was attributed to concomitant colistin or
aminoglycoside treatment [16, 45]. One study
reported elevated liver enzymes which were
attributed to host factors (severity of illness) and
not to the minocycline [46]. Two other studies
reported no adverse reactions or events attrib-
uted to minocycline [42].
DISCUSSION
Acinetobacter species are common nosocomial
pathogens that have been implicated in serious
infections associated with high morbidity and
mortality rates. Historically, carbapenems were
used to treat MDR Acinetobacter infections, but
in recent years an increase in CRAB has
decreased the therapeutic effectiveness of these
agents. Limitations of available treatment
options have left clinicians in need of addi-
tional therapeutic choices. During the last dec-
ade, the interest in minocycline has increased
due to its in vitro activity against A. baumannii
(including MDR and XDR strains), as well as its
pharmacokinetic and pharmacodynamic prop-
erties (e.g., its ability to achieve good serum and
tissue levels as well as to display bactericidal
activity). The ability of minocycline to over-
come many resistance mechanisms that
decrease the activity of other tetracyclines, most
notably TetA and RND pumps, has allowed for
its more widespread use against MDR Acineto-
bacter. Its favorable safety profile, lack of needed
dose adjustments for renal and hepatic failure,
and the easy conversion between IV to PO for-
mulations have enhanced its clinical appeal.
This is particularly true for difficult to manage
patients with resistant Acinetobacter infections
where available data support therapeutic suc-
cess in these challenging clinical scenarios.
Given the paucity of antimicrobials currently
available to treat MDR and XDR A. baumannii,
further clinical and laboratory evaluation of
minocycline as an effective treatment alterna-
tive for infections caused by resistant pathogens
is warranted. Additionally, further studies to
assess if minocycline monotherapy is sufficient
or whether it should be utilized as part of a
combination therapeutic regimen are needed.
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